147 related articles for article (PubMed ID: 36055292)
1. The promise of paediatric dolutegravir in Zimbabwe.
Makoni M
Lancet HIV; 2022 Sep; 9(9):e603-e604. PubMed ID: 36055292
[No Abstract] [Full Text] [Related]
2. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
3. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
Karabay O
AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
[No Abstract] [Full Text] [Related]
4. Dolutegravir drug-resistance monitoring in Africa.
Kouamou V; Inzaule S; Manasa J
Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
[No Abstract] [Full Text] [Related]
5. Dolutegravir for children with HIV-associated tuberculosis.
Meyers T; Krogstad P
Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
[No Abstract] [Full Text] [Related]
6. Compelling evidence for unconditional shift to dolutegravir.
Steegen K; Hans L
Lancet HIV; 2022 Aug; 9(8):e523-e524. PubMed ID: 35905750
[No Abstract] [Full Text] [Related]
7. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
[No Abstract] [Full Text] [Related]
8. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
9. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
[No Abstract] [Full Text] [Related]
10. Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.
Crawford M; van Wyk J; Aboud M; Vannappagari V; Romach B; Curtis L; Wynne B; de Ruiter A; Smith K; Payvandi N
J Acquir Immune Defic Syndr; 2020 Jan; 83(1):e2-e5. PubMed ID: 31809366
[No Abstract] [Full Text] [Related]
11. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
12. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
13. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
14. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
[No Abstract] [Full Text] [Related]
15. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Paparizos V; Vasalou V; Kourkounti S
Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
[No Abstract] [Full Text] [Related]
16. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
Raffi F; Wainberg MA
Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir monotherapy as maintenance ART bites the dust.
Trevillyan JM; Hoy JF
Lancet HIV; 2017 Dec; 4(12):e531-e532. PubMed ID: 29107563
[No Abstract] [Full Text] [Related]
18. Real world use of dolutegravir two drug regimens: Erratum.
AIDS; 2023 May; 37(6):1019. PubMed ID: 37017026
[No Abstract] [Full Text] [Related]
19. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir: first global approval.
Ballantyne AD; Perry CM
Drugs; 2013 Sep; 73(14):1627-37. PubMed ID: 24052331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
